Activists from the AIDS Healthcare Foundation (AHF) held a protest outside Food and Drug Administration (FDA) headquarters because of their denied access to review Gilead Science's application for Truvada as pre-exposure prophylaxis (PrEP), according to an AHF statement. AHF filed a Freedom of Information Act request in 2011 to look at correspondence between the FDA and Gilead. AHF believes that FDA approval is unnecessary based on current clinical trial results and the serious health risks the daily pills pose for HIV-negative people.

To read the AHF statement, click here.